5.220EUR-2.25%Mkt Cap: 146.16M EURP/E: —Last update: 2026-05-14
Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for p…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)10.33
PEG—
P/B5.47
P/S16.55
EV/EBITDA-19.46
EV/Revenue14.96
EPS (TTM)-0.24
EPS (Forward)0.51
Cash Flow & Leverage
FCF Yield-4.46%
FCF Margin-73.88%
Operating CF-6.90M EUR
CapEx (TTM)297.00K EUR
Net Debt/EBITDA1.86
Net Debt-12.66M EUR
Technical
SMA 505.423 (-3.7%)
SMA 2006.203 (-15.8%)
Beta0.65
S&P 52W Chg24.23%
Avg Vol (30d)6.58K
Avg Vol (10d)3.14K
Technical Indicators
RSI (14)46.6
MACD-0.0885
MACD Signal-0.1135
MACD Hist.+0.0250
BB Upper5.992 EUR
BB Middle5.381 EUR
BB Lower4.771 EUR
BB Width22.70%
ATR (14)0.2384 EUR
Vol Ratio (20d)0.33x
52W Range
4.51018% of range8.400
52W High8.400 EUR
52W Low4.510 EUR
Profitability
Gross Margin97.32%
EBITDA Margin-76.87%
Profit Margin-74.98%
Oper. Margin-76.19%
ROE-19.73%
ROA-15.34%
Revenue Growth7.30%
Earnings Growth—
Balance Sheet
Debt/Equity0.06
Current Ratio3.89
Quick Ratio3.85
Book Value/Sh0.9550 EUR
Cash/Share0.5140 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.28.00M
Float11.36M
Insiders58.14%
Institutions0.01%
Analyst Consensus
Rating—
Target (Mean)13.57 EUR
Target Range6.000 EUR – 20.40 EUR
# Analysts3
Company
Market Cap146.16M EUR
Enterprise Value132.10M EUR
Revenue (TTM)8.83M EUR
Gross Profit8.23M EUR
Net Income (TTM)-6.34M EUR
Revenue/Share0.3210 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees55
Last Price5.220 EUR
CountryBE
SectorHealthcare
IndustryBiotechnology
ISIN—